Baylin and co-workers have shown that the combination of the histone deacetylase (HDAC) inhibitor trichostatin A with decitabine is more effective in reactivating transcription of epigenetically silenced genes such as hMLH1 in tumour cell lines than either drug alone (Cameron et al, 1999). This evidence concerns the gene MLH1 and neoplasm.